By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said it demonstrated that VXX-401 lowers LDL cholesterol, supporting its potential for treating hypercholesterolemia. The VXX-401, a synthetic peptide vaccine, aims to provide a safe and effective solution against heart disease by targeting PCSK9, the company said in a statement. The studies were published in the Journal of […]

Related Keywords

Daniella Parra , Nasdaq , Vaxxinity Inc , Journal Of Lipid Research , Lipid Research , Vldl Cholesterol , Heart Disease , Vaxxinity , Synthetic Peptide Vaccine , Effective Solution , Pcsk9 , Vaxx , Cholesterol ,